Cargando…

Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer

Chemokines (chemotactic cytokines) promote leukocyte attraction to sites of inflammation and cancer. Certain chemokines promote and regulate neoplastic progression, including metastasis and angiogenesis. One such chemokine, CXCL10, was found to be expressed in colorectal cancer (CRC) tissue. To gain...

Descripción completa

Detalles Bibliográficos
Autores principales: DIMBERG, JAN, SKARSTEDT, MARITA, LÖFGREN, STURE, ZAR, NIKLAS, MATUSSEK, ANDREAS
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990219/
https://www.ncbi.nlm.nih.gov/pubmed/24748971
http://dx.doi.org/10.3892/br.2014.255
_version_ 1782312249764872192
author DIMBERG, JAN
SKARSTEDT, MARITA
LÖFGREN, STURE
ZAR, NIKLAS
MATUSSEK, ANDREAS
author_facet DIMBERG, JAN
SKARSTEDT, MARITA
LÖFGREN, STURE
ZAR, NIKLAS
MATUSSEK, ANDREAS
author_sort DIMBERG, JAN
collection PubMed
description Chemokines (chemotactic cytokines) promote leukocyte attraction to sites of inflammation and cancer. Certain chemokines promote and regulate neoplastic progression, including metastasis and angiogenesis. One such chemokine, CXCL10, was found to be expressed in colorectal cancer (CRC) tissue. To gain insight into the prognostic significance of CXCL10, we investigated whether the levels of this chemokine were altered in the colorectal tissue or plasma of CRC patients. Using Luminex technology for protein analyses, we observed a significantly higher CXCL10 protein level in cancer tissue compared to that in paired normal tissue. Moreover, significantly higher plasma levels of CXCL10 were detected in patients compared to those in control subjects and the plasma levels of CXCL10 in disseminated disease were found to be significantly higher compared to those in localized disease. The single-nucleotide polymorphism rs8878, which has been described in exon 4 in the 3′-untranslated region of the CXCL10 gene, was investigated using a TaqMan system. There were significant differences in genotype distribution and allelic frequencies between CRC patients and control subjects. In conclusion, altered CXCL10 protein concentrations in CRC tissues or plasma and the rs8878 genotype variant of CXCL10 may contribute to the prediction of clinical outcome.
format Online
Article
Text
id pubmed-3990219
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-39902192014-04-18 Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer DIMBERG, JAN SKARSTEDT, MARITA LÖFGREN, STURE ZAR, NIKLAS MATUSSEK, ANDREAS Biomed Rep Articles Chemokines (chemotactic cytokines) promote leukocyte attraction to sites of inflammation and cancer. Certain chemokines promote and regulate neoplastic progression, including metastasis and angiogenesis. One such chemokine, CXCL10, was found to be expressed in colorectal cancer (CRC) tissue. To gain insight into the prognostic significance of CXCL10, we investigated whether the levels of this chemokine were altered in the colorectal tissue or plasma of CRC patients. Using Luminex technology for protein analyses, we observed a significantly higher CXCL10 protein level in cancer tissue compared to that in paired normal tissue. Moreover, significantly higher plasma levels of CXCL10 were detected in patients compared to those in control subjects and the plasma levels of CXCL10 in disseminated disease were found to be significantly higher compared to those in localized disease. The single-nucleotide polymorphism rs8878, which has been described in exon 4 in the 3′-untranslated region of the CXCL10 gene, was investigated using a TaqMan system. There were significant differences in genotype distribution and allelic frequencies between CRC patients and control subjects. In conclusion, altered CXCL10 protein concentrations in CRC tissues or plasma and the rs8878 genotype variant of CXCL10 may contribute to the prediction of clinical outcome. D.A. Spandidos 2014-05 2014-03-17 /pmc/articles/PMC3990219/ /pubmed/24748971 http://dx.doi.org/10.3892/br.2014.255 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
DIMBERG, JAN
SKARSTEDT, MARITA
LÖFGREN, STURE
ZAR, NIKLAS
MATUSSEK, ANDREAS
Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer
title Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer
title_full Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer
title_fullStr Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer
title_full_unstemmed Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer
title_short Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer
title_sort protein expression and gene polymorphism of cxcl10 in patients with colorectal cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990219/
https://www.ncbi.nlm.nih.gov/pubmed/24748971
http://dx.doi.org/10.3892/br.2014.255
work_keys_str_mv AT dimbergjan proteinexpressionandgenepolymorphismofcxcl10inpatientswithcolorectalcancer
AT skarstedtmarita proteinexpressionandgenepolymorphismofcxcl10inpatientswithcolorectalcancer
AT lofgrensture proteinexpressionandgenepolymorphismofcxcl10inpatientswithcolorectalcancer
AT zarniklas proteinexpressionandgenepolymorphismofcxcl10inpatientswithcolorectalcancer
AT matussekandreas proteinexpressionandgenepolymorphismofcxcl10inpatientswithcolorectalcancer